Jointly sponsored by ACCP and the American Society of Health-System Pharmacists

• Session Overview
• Program Content
• Faculty
• Target Audience and Program Goals
• CPE Credit
• BCOP Specialty Recertification Credit
• Technical Requirements
• Fees

This educational series explores cutting-edge, contemporary therapeutic topics, and demonstrates scientifically sound clinical reasoning and decision-making. It employs learning activities designed to advance the participants’ skills and abilities to critically evaluate the scientific evidence and to effectively incorporate into daily practice significant findings that lead to effective and safe patient care.

The 2018 BCOP Clinical Sessions are offered in two parts. The first part is focused Cardiology-Oncology and the second part of the BCOP Clinical Sessions will examine Immunotherapy.

	Sandra Cuellar Puri, Pharm.D., BCOP Clinical Assistant Professor, University of Illinois Medical Center; Clinical Oncology Pharmacist, University Illinois at Chicago, Chicago, Illinois
	Jo Ellen Rodgers, Pharm.D., FCCP, FAHA, FHFSA, BCPS-AQ Cardiology Clinical Professor, Division of Pharmacotherapy and Experimental Therapeutics, School of Pharmacy, University of North Carolina, Chapel Hill, North Carolina
	James E. Tisdale, Pharm.D., FCCP, FAPhA, FNAP, FAHA, BCPS Professor, Department of Pharmacy Practice, College of Pharmacy, Purdue University, and Adjunct Professor, School of Medicine, Indiana University, Indianapolis, Indiana
	Jenna M. Carmichael, Pharm.D., BCOP Clinical Pharmacist, MTDM Oral Chemotherapy; RPD, PGY2 Oncology Residency Program; Geisinger Health, Wilkes-Barre, Pennsylvania
	Tanya J. Uritsky, Pharm.D., BCPS, CPE Clinical Pharmacy Specialist Pain Management and Palliative Care Hospital of the University of Pennsylvania, Bryn Mawr, Pennsylvania

Clinical Pharmacists and BCOPs providing care to patients with cancer.

At the conclusion of the program, the participant should be able to:

Advances in Cardio-Oncology: Prevention and Management of Cardiovascular Complications Associated with Anticancer Therapies

1. Identify risk factors for chemotherapy-associated heart failure (HF) and differentiate this risk among the various chemotherapies.
2. Compare and contrast various diagnostic tools for identifying chemotherapy-associated HF.
3. Identify various strategies to minimize the risk of chemotherapy-associated HF.
4. Describe the role of pharmacotherapy in the primary and secondary prevention of chemotherapy-associated HF.
5. Review anticancer therapies that cause vascular toxicities.
6. Describe pathophysiology of anticancer therapies induced vascular toxicities.
7. Describe monitoring and management of vascular toxicities cause by anticancer therapy.
8. Describes the types of arrhythmias that may be caused by cancer chemotherapy drugs.
9. Describe the pathophysiology and adverse outcomes associated with cancer chemotherapy-associated arrhythmias.
10. Describe strategies for prevention and management of cancer chemotherapy-associated arrhythmias.

Do You Immuno? Supporting Patients with Advanced Malignancy Receiving Immunotherapy – From Symptom Management to Effective Communication and Beyond!

1. List current indications for immunotherapy in oncology.
2. Summarize potential adverse effects of immunotherapies.
3. Review new ASCO and ESMO guidelines on supportive care management.
4. Develop a supportive care plan for a patient experiencing adverse effects from immunotherapy, including agent selection and monitoring parameters.
5. Describe the ethical considerations around utilization of immunotherapies in advanced illness.
6. Given a patient case, describe the elements of a short, effective counseling session pertaining to initiation and monitoring for patients starting immunotherapy treatments.

The American College of Clinical Pharmacy is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education.

Both BCOP Clinical Sessions are application-based activities.

BCOP Clinical Sessions—Advances in Cardio-Oncology: Prevention and Management of Cardiovascular Complications Associated with Anticancer Therapies
Activity Number: 0217-9999-18-158-H01-P
2.0 Hours of CPE Credit

BCOP Clinical Sessions—Do You Immuno? Supporting Patients with Advanced Malignancy Receiving Immunotherapy – From Symptom Management to Effective Communication and Beyond!
Activity Number: 0217-9999-18-165-H01-P
2.0 Hours of CPE Credit

To earn continuing pharmacy education (CPE) credit and to receive your continuing pharmacy education statement of credit for this activity, participants must successfully complete a Web-based posttest by October 1, 2019. Partial credit is not available for each activity.

To be eligible for 4.0 CPE hours of recertification credit, BCOPs must listen to all 4.0 contact hours of the recorded presentations and then successfully complete a Web-based posttest by March 31, 2019. Partial credit is available for this activity.

ACCP, as the official provider approved by BPS, will record and report recertification credit earned for this activity directly to BPS.

Requires an Internet browser and Adobe Reader.
 

No financial support from external supporters was obtained for this course.